Targeted cancer therapies differ from traditional chemotherapy in one fundamental way: they aim at specific molecules that drive cancer growth rather than broadly attacking fast-dividing cells. But "targeted therapy" is not one thing. Small-molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and oncolytic viruses work through distinct mechanisms, and the physical size of each drug largely determines where it can act — inside the cell or only on its surface. Understanding that distinction is the key to following modern oncology.

Targeted Therapy 101: The Basics ExplainedTo provide a foundational visual explanation of targeted therapy basics for readers seeking an alternative learning format.Watch on YouTube

Small-Molecule Inhibitors: Targeting Within the Cell

Small-molecule inhibitors are lab-made chemicals small enough to slip through the cell membrane. Once inside a cancer cell, they block a specific biomarker or substance, preventing the cell from growing and spreading, as the American Cancer Society explains. Their generic names typically end in "-ib," such as imatinib.

A review for primary care physicians notes that these drugs owe their intracellular reach to their low molecular weight, letting them pass through the cell surface to reach targets inside and slow proliferation or trigger tumor cell death. Many are kinase or protease inhibitors, and their names often end in "-nib" or "-mib" — examples include bortezomib, osimertinib, and vemurafenib.

The practical consequence is straightforward: when the cancer's driver is an intracellular signaling protein, a small molecule is often the right tool. A review of molecular targeted therapy notes that small-molecule agents acting as signal transduction inhibitors have become a backbone of precision cancer medicine and are now used as first-line therapy for various human cancers, with efficient anticancer effects and fewer side effects than conventional chemotherapy.